Moreover, we further revealed that IL-37 protected against structural remodeling by inhibiting IL-24-mediated EMT by regulating the ERK1/2 and STAT3 signaling pathways, which might provide a theoretical basis for the development of IL-37 as a therapeutic agent and reveal possible drug targets to prevent and treat asthma airway remodeling. The gene discussed is MAPK3; the disease is asthma.